StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXFree Report) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 2.8 %

NYSE:BTX opened at $1.04 on Friday. The company has a market capitalization of $61.18 million, a PE ratio of -0.46 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10. The stock has a fifty day simple moving average of $1.57 and a 200-day simple moving average of $1.87.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Read More

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.